NOAELPLATIN
LIVE

Serial Number

79290136

Owner

CnPharm Co., Ltd.

Attorney

Lenny R. Jiang

Filing Date

Jun 16, 2020

Add to watchlist:

No watchlists yet
View on USPTO

NOAELPLATIN Trademark

Serial Number: 79290136 • Registration: 6398898

NOAELPLATIN is a trademark filed by CnPharm Co., Ltd. on June 16, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CnPharm Co., Ltd. (16 trademarks)

B-455, 52, Ewhayeodae-gil, Seodaemun-gu

Entity Type: 03

Trademark Details

Filing Date

June 16, 2020

Registration Date

June 29, 2021

Published for Opposition

April 13, 2021

Cancellation Date

March 4, 2022

Goods & Services

Pharmaceutical preparations for the treatment of pancreatic tumors; pharmaceutical agents for the treatment of disorders in sensory organs; thyroid and para-thyroid hormone preparations; medicinal tonics for the treatment of pancreatic tumors; oral contraceptive pills; antiemetics; local anesthetics; bronchodilating preparations; anti-cough drops; androgen preparations; pituitary hormone preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents for use in regulating metabolism; vaccines against flu; chilblain preparations; pharmaceutical preparations for headache; anesthetics; pharmaceutical for use in the treating disorders of the peripheral nervous system; pharmaceutical preparations for immunity adjustment; nutritive substances for microorganisms for medical purposes; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations for treating disorders of the urogenital organs; vitamin preparations; pharmaceutical preparations for the treatment of bone diseases; anti-inflammatory and antipyretic preparations; pharmaceutical agents for treating disorders of the digestive organs; pharmaceutical preparations for the treatment of cardiovascular disorders; nervines; ophthalmic preparations; allergy medications; chemico-pharmaceutical preparations for the treatment of pancreatic disorders; medicines for the treatment of gastrointestinal diseases; mineral injection preparations featuring vitamin supplements for medical purposes; antioxidants for medical purposes; haematogen; pharmaceutical preparations for tumor treatment; multivitamin preparations; laxative suppositories; pharmaceutical preparations for use in the treatment of disorders of the central nervous system; pharmaceutical preparations for diagnosis of cancer; sedatives; analgesics; vaginal washes for medical purposes; pharmaceutical preparations for treating asthma; medicines for treating tooth pain; hemorrhoid preparations; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; vaccines against pneumococcal infections; dermatological pharmaceutical products; contraceptive preparations; antihypertensives; anti-uric preparations; anti-diabetic pharmaceuticals; pharmaceutical preparations for treatment of hemorrhoids; antibiotic preparations; antibiotics; anti-cancer preparations; anti-cancer treatment supplements; antidepressants; anticoagulants; antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; febrifuges; vasoconstrictors; hypoglycemic agents; blood solvent being preparations for treating blood disorders; pharmaceutical preparations for treating disorders of the respiratory organs; respiratory stimulant preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for treating respiratory diseases and asthma; mixed vitamin preparations; preparations for the treatment of burns; disinfectants for chemical toilets; chemotherapeutics; preparations for treatment of hepatitis; preparations for treating colds; preparations for the treatment of hyperlipidemia; preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of osteoporosis; preparations for the treatment of osteoporosis; injectable pharmaceuticals for treatment of anaphylactic reactions; pharmaceutical preparations for treating halitosis; nausea treatment preparations; antiulcerants; pharmaceutical preparations for the treatment of musculoskeletal disorders; preparations for the treatment of muscle fatigue; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for the treatment of rhinitis; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; pharmaceutical preparations for the treatment of cancerous cells; medicines for treating intestinal disorders; cardiovascular treatment preparations; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for treating allergies; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; medicated preparations for the treatment of mouth disorders; transdermal patches for medical treatment of nausea; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of gout; drug delivery agents in the form of dissolvable films, coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents consisting of compounds that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Mar 20, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Mar 20, 2022 DETH
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 23, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 28, 2021 FICS
FINAL DISPOSITION PROCESSED
Oct 28, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 29, 2021 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Sep 3, 2021 NREP
REVIEW OF CORRESPONDENCE COMPLETE - CERTIFICATE OF REG MAILED
Jul 12, 2021 CORV
REGISTERED-PRINCIPAL REGISTER
Jun 29, 2021 R.PR
JURISDICTION RESTORED TO EXAMINING ATTORNEY
May 19, 2021 JURT
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 13, 2021 NPUB
PUBLISHED FOR OPPOSITION
Apr 13, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Apr 12, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 24, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 24, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 24, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 9, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 4, 2021 CRFA
ASSIGNED TO LIE
Mar 2, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 1, 2020 TROA
REFUSAL PROCESSED BY IB
Nov 8, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 21, 2020 RFCS
REFUSAL PROCESSED BY MPU
Oct 21, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 24, 2020 RFCR
NON-FINAL ACTION WRITTEN
Sep 23, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 18, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 28, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 24, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 23, 2020 REPR